Literature DB >> 16453324

Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody.

Anna Rostedt Punga1, Roland Flink, Håkan Askmark, Erik V Stålberg.   

Abstract

A 75-year-old man with severe oculobulbar myasthenia gravis (MG) treated with acetylcholine esterase inhibitors (AChEIs) was found to have muscle-specific tyrosine kinase (MuSK) antibodies. Neurophysiological examination displayed extra repetitive discharges after the compound motor action potential (CMAP) at low-frequency stimulation, possibly triggered by AChEI. This indicates an abnormal sensitivity to acetylcholine in patients with MuSK antibodies and may be a useful indicator of the adverse effect of AChEI treatment in these patients.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16453324     DOI： 10.1002/mus.20515

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN： 0148-639X            Impact factor:   3.217


  14 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 2.  Treatment of myasthenia gravis: focus on pyridostigmine.

Authors:  Lorenzo Maggi; Renato Mantegazza
Journal:  Clin Drug Investig       Date:  2011-10-01       Impact factor: 2.859

Review 3.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

4.  Indication of peripheral nerve hyperexcitability in adult-onset subacute sclerosing panencephalitis (SSPE).

Authors:  Annabel Schreurs; Erik V Stålberg; Anna Rostedt Punga
Journal:  Neurol Sci       Date:  2008-05-16       Impact factor: 3.307

5.  Current and emerging therapies for the treatment of myasthenia gravis.

Authors:  Renato Mantegazza; Silvia Bonanno; Giorgia Camera; Carlo Antozzi
Journal:  Neuropsychiatr Dis Treat       Date:  2011-03-22       Impact factor: 2.570

6.  Juvenile myasthenia gravis: a paediatric perspective.

Authors:  Maria F Finnis; Sandeep Jayawant
Journal:  Autoimmune Dis       Date:  2011-11-01

7.  Treatment of MuSK-Associated Myasthenia Gravis.

Authors:  Khalid El-Salem; Ahmed Yassin; Kefah Al-Hayk; Salma Yahya; Duha Al-Shorafat; Said S Dahbour
Journal:  Curr Treat Options Neurol       Date:  2014-04       Impact factor: 3.972

8.  Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.

Authors:  Shin Joong Oh
Journal:  J Clin Neurol       Date:  2009-06-30       Impact factor: 3.077

9.  Clinical and Electrophysiologic Responses to Acetylcholinesterase Inhibitors in MuSK-Antibody-Positive Myasthenia Gravis: Evidence for Cholinergic Neuromuscular Hyperactivity.

Authors:  Ha Young Shin; Hyung Jun Park; Hyo Eun Lee; Young-Chul Choi; Seung Min Kim
Journal:  J Clin Neurol       Date:  2014-04-23       Impact factor: 3.077

10.  The Myotonic Plot Thickens: Electrical Myotonia in Antimuscle-Specific Kinase Myasthenia Gravis.

Authors:  Marcus Magnussen; Ioannis Karakis; Taylor B Harrison
Journal:  Case Rep Neurol Med       Date:  2015-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.